T1	Participants 75 132	early-stage non-small-cell lung cancer (IFCT 0002 trial).
T2	Participants 282 338	resectable StageI-II non-small-cell lung cancer (NSCLC).
T3	Participants 838 869	RESULTS A total of 528 patients
T4	Participants 2035 2055	in early-stage NSCLC
